Financing ·
Parabilis Medicines, Inc. entered into a Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc. for the…
PBLSParabilis Medicines, Inc.
Parabilis Medicines, Inc. entered into a Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc. for the purchase of 4,166,666 shares of common stock at $18.00 per share, representing 90% of the $20.00 IPO price. The private placement closed on June 11, 2026, and the company's certificate of incorporation and bylaws were amended and restated to authorize 800,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. Parabilis Medicines, Inc. is a biotechnology company focused on developing and commercializing medicines.